These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mechanisms for hyperglycemia in type II diabetes mellitus: therapeutic implications for sulfonylurea treatment--an update. Porte D; Kahn SE Am J Med; 1991 Jun; 90(6A):8S-14S. PubMed ID: 1872310 [TBL] [Abstract][Full Text] [Related]
3. [Factors responsible for fasting hyperglycemia in the non-insulin-dependent diabetic patient]. Tappy L Rev Med Suisse Romande; 1993 Sep; 113(9):699-701. PubMed ID: 8210897 [No Abstract] [Full Text] [Related]
4. Combining insulin and oral agents in diabetes: indications and controversies. Rosenthal TC Am Fam Physician; 1992 Dec; 46(6):1721-7. PubMed ID: 1456195 [TBL] [Abstract][Full Text] [Related]
6. The clinical use of oral sulfonylureas in the management of non-insulin dependent diabetes mellitus (NIDDM). Ponte CD W V Med J; 1990 Oct; 86(10):455-8. PubMed ID: 2238629 [TBL] [Abstract][Full Text] [Related]
7. Oral antidiabetic agents. The emergence of alpha-glucosidase inhibitors. Lebovitz HE Drugs; 1992; 44 Suppl 3():21-8. PubMed ID: 1280574 [TBL] [Abstract][Full Text] [Related]
8. [Therapeutic management of the secondary failure of sulfonylurea therapy]. Sauer H Dtsch Med Wochenschr; 1985 Jan; 110(1):27-30. PubMed ID: 3880697 [No Abstract] [Full Text] [Related]
9. [Increased blood sugar in type 2 diabetes mellitus: what now?]. Winter T Praxis (Bern 1994); 2002 Mar; 91(12):498-502. PubMed ID: 11974431 [TBL] [Abstract][Full Text] [Related]
10. Effect of sulfonylurea withdrawal on proinsulin levels, B cell function, and glucose disposal in subjects with noninsulin-dependent diabetes mellitus. Prigeon RL; Jacobson RK; Porte D; Kahn SE J Clin Endocrinol Metab; 1996 Sep; 81(9):3295-8. PubMed ID: 8784086 [TBL] [Abstract][Full Text] [Related]
11. Oral hypoglycemic agents in type II diabetes mellitus. Lubbos H; Miller JL; Rose LI Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707 [TBL] [Abstract][Full Text] [Related]
12. Treatment of NIDDM with insulin agonists or substitutes. Galloway JA Diabetes Care; 1990 Dec; 13(12):1209-39. PubMed ID: 1980453 [TBL] [Abstract][Full Text] [Related]
13. Combination insulin-sulfonylurea therapy in type II diabetes mellitus. Allen BT; Feinglos MN South Med J; 1987 Oct; 80(10):1285-9. PubMed ID: 3310252 [No Abstract] [Full Text] [Related]
15. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Haffner SM Endocr Rev; 1998 Oct; 19(5):583-92. PubMed ID: 9793758 [No Abstract] [Full Text] [Related]
16. Rationale for the association of sulfonylurea and insulin. Del Prato S Am J Med; 1991 Jun; 90(6A):77S-82S. PubMed ID: 1872309 [TBL] [Abstract][Full Text] [Related]
17. Influence of oral sulfonylurea agents on hepatic glucose uptake. Kawamori R; Morishima T; Kubota M; Matsuhisa M; Ikeda M; Kamada T Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S109-13. PubMed ID: 8529503 [TBL] [Abstract][Full Text] [Related]
18. Strategies for insulin therapy in type 2 diabetes. Edelman SV; Morello CM South Med J; 2005 Mar; 98(3):363-71. PubMed ID: 15813164 [TBL] [Abstract][Full Text] [Related]
19. Insulin and oral sulfonylureas in the treatment of diabetes mellitus. White JR Am Pharm; 1992 Aug; NS32(8):39-43. PubMed ID: 1524021 [No Abstract] [Full Text] [Related]
20. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients. van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]